HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jan J. Andreasen Conny Nielsen Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Andreasen, J. J. Articles by Nielsen, C. Search for Related Content PubMed PubMed Citation Articles by Andreasen, J. J. Articles by Nielsen, C. Related Collections Cardiac - other Coronary disease

Eur J Cardiothorac Surg 2004;26:311-317
© 2004 Elsevier Science NL

Prophylactic tranexamic acid in elective, primary coronary artery bypass surgery using cardiopulmonary bypass

Department of Cardiothoracic Surgery, Aalborg University Hospital, University of Aarhus, Hobrovej, Postboks 365, DK-9100 Aalborg, Denmark

Received 14 January 2004; received in revised form 29 February 2004; accepted 15 March 2004.

^* Corresponding author. Tel.: +45-99-322964; fax: +45-99-322425
e-mail: jjandreasen{at}dadlnet.dk

Objective: Perioperative use of tranexamic acid (TA), a synthetic antifibrinolytic drug, decreases perioperative blood loss, and the proportion of patients receiving blood transfusion in cardiac surgery, but the results may vary in different clinical settings. The primary objective of the present study was to determine the efficacy of TA to decrease chest tube drainage and the proportion of patients requiring perioperative allogeneic transfusions following primary, elective, on-pump coronary artery bypass grafting (CABG) in patients with a low baseline risk of postoperative bleeding. Methods: In a double-blinded, prospective, placebo-controlled study, 46 patients were randomized into two groups. One group received TA 1.5 g as a bolus, followed by a constant infusion of 200 mg/h until 1.5 g. The other group received placebo (0.9% saline). Among exclusion criteria were treatment with acetylsalicylic acid, non-steroidal anti-inflammatory drugs or other platelet inhibitors within 7 days before surgery. Results: Preoperative demographics, biochemical and surgical characteristics were comparable between groups. At 6 h postoperatively, there was a trend towards a greater blood loss (median and interquartile range) in the placebo group (710 and 460–950 ml) compared to the TA group (400 and 350–550 ml), but the difference did not reach statistical significance. Neither were transfusion rates and the amount of autotransfused shed mediastinal blood different between the groups postoperatively. Postoperative D-dimer concentrations were significantly higher in the placebo group compared to the TA group (P<0.001). This difference could not be explained by differences in the amount of autotransfused shed mediastinal blood alone. Plasma concentrations of ß-thromboglobulin and platelet factor 4 were significantly increased postoperatively in both groups, but without any intergroup differences. Seven patients (15%), one in the TA group and six in the placebo group, were reoperated due to excessive bleeding. Surgical correctable bleeding was found in all except two patients from the placebo group. Conclusions: An antifibrinolytic effect following prophylactic use of TA in elective, primary CABG among patients with a low risk of postoperative bleeding, did not result in any significant decrease in postoperative bleeding compared to a placebo group.

Key Words: Coronary artery bypass grafting • Tranexamic acid • Placebo • Bleeding

This article has been cited by other articles:

				T. Shinghal, D. Bracco, N. Noiseux, I. Prieto, F. Basile, and T M Hemmerling 44531 - TRANEXAMIC ACID REDUCES BLOOD LOSS AFTER OFF-PUMP CORONARY ARTERY BYPASS GRAFTING: A DOUBLE BLIND PLACEBO CONTROLLED STUDY Can J Anesth, August 1, 2007; 54(suppl_1): 44531 - 44531. [Abstract] [Full Text] [PDF]

				J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF]

				The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]

				T. Vanek, M. Jares, R. Fajt, Z. Straka, K. Jirasek, M. Kolesar, P. Brucek, and M. Maly Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo) Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 563 - 568. [Abstract] [Full Text] [PDF]